Perrigo
Headquartered in Ireland, Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products and receives royalties from Multiple Sclerosis drug Tysabri.
In 2013 it acquired Irish pharma company Elan.
Financial Data
-
31st Dec 18 Source: CRO
- €4.2 billion turnover
-
€255.3 million
profit - 10,400 employees
-
31st Dec 17 Source: CRO
- €4.1 billion turnover
-
€229.2 million
profit - 10,400 employees
- 4 more years available »
Ranking
By Turnover
(€4.2 billion)- 29th in Top Companies
- 6th in Health
- 5th in Pharma
By Employees
(10,400)- 22nd in Top Companies
- 4th in Health
- 4th in Pharma
-
- 10,400
- €4.2 billion
Employees
- Murray S. Kessler CEO/Managing Director
Latest News
- 11:10am EML secures €105m discount on deal for Irish fintech on back of Covid-19 crisis
- 11:00am Couple in mortgage legal-fees dispute get €10,000 compensation
- 10:16am Irish heart drug group Amarin slumps 70% over patent suit loss
- 9:40am UK mergers watchdog clears Paddy Power owner’s €12bn Stars deal
- 9:34am Shell slows refining, takes up to $800m hit after oil crash